NCT06018311 (HACER) is a NA clinical trial of Exercising together in Neoplasms, sponsored by University of Arizona.

Who is sponsoring NCT06018311?

NCT06018311 is sponsored by University of Arizona.

What drugs are being tested in NCT06018311?

Interventions in NCT06018311: Exercising together.

What condition does NCT06018311 study?

NCT06018311 studies Neoplasms, Prostate Cancer, Exercise, Caregiver Burden, Cancer Survivors.

Is NCT06018311 still recruiting?

NCT06018311 is currently active, enrolled. Last updated 20 March 2026.

Last reviewed 2026-03-20 · How we verify

NCT06018311: HACER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hispanic Adapted and Culturally Relevant Exercising Together

Active, enrolled NA Last updated 20 March 2026

What this trial tests

NA trial testing Exercising together in Neoplasms in 58 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 November 2023

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	University of Arizona
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	58
Start date	1 November 2023
Primary completion	31 December 2026
Estimated completion	31 December 2026
Sites	1 location across United States

Drugs / interventions tested

Exercising together

Conditions studied

Neoplasms — all drugs for Neoplasms →
Prostate Cancer — all drugs for Prostate Cancer →
Exercise — all drugs for Exercise →
Caregiver Burden — all drugs for Caregiver Burden →

Sponsor

University of Arizona

Who can join

Adults 18 to 99, any sex, with Neoplasms or Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the feasibility and effects of an adapted Exercising Together, a partnered resistance training program, on the physical and mental health of prostate cancer survivors and their informal caregiver. The Exercising Together program is designed to promote teamwork during supervised group exercise classes delivered remotely through videoconferencing software. The intervention period will be 3-months with a 3-month follow-up.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A Pilot Feasibility Study of a Group-Based Remote-Delivered Dyadic Exercise Intervention in Hispanic Men With Prostate Cancer and Their Caregivers.
Skiba MB, Contreras J, Nelson MA, Recio-Boiles A, et al · · 2026 · PMID 41795592 · DOI 10.1002/cam4.71709

Verify or expand the search:

Other recruiting trials for Neoplasms

Currently open trials in the same condition.

NCT07438782 — First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combinatio · Phase 1 · recruiting
NCT07382817 — Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms · Phase 1 · recruiting
NCT07277270 — A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tum · Phase 1 · recruiting
NCT07257640 — IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia · Phase 1 · recruiting
NCT07213609 — A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer · Phase 1, PHASE2 · recruiting

Other University of Arizona trials

Trials by the same sponsor.

NCT04062890 — Inhibiting GABA Transaminase to Relieve Obesity Induced Hyperinsulinemia and Insulin Resistance · Phase 2 · withdrawn
NCT05569486 — Elucidating the Central Mechanisms of Action for Green Light Therapy in Managing Chronic Pain · NA · not yet recruiting
NCT05064111 — Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy · suspended
NCT06567899 — Mechanistic Underpinnings of Preeclampsia · not yet recruiting
NCT07254793 — Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06018311 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Arizona
Last refreshed: 20 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06018311.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing